On Nov. 9, 2021, Novan announced promising preclinical safety results with berdazimer sodium in a 14-day GLP repeat dose intranasal toxicity study.

These findings complimented the previous positive preclinical efficacy results observed in deterring transmission from SARS-CoV-2-infected golden Syrian hamsters. The Company was continuing to progress the development of its potential anti-viral therapy against COVID-19.